These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 30506342)

  • 1. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
    de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
    Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
    Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
    PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-mutagenic Ru(ii) complexes: cytotoxicity, topoisomerase IB inhibition, DNA and HSA binding.
    da Silva MM; de Camargo MS; Correa RS; Castelli S; De Grandis RA; Takarada JE; Varanda EA; Castellano EE; Deflon VM; Cominetti MR; Desideri A; Batista AA
    Dalton Trans; 2019 Oct; 48(39):14885-14897. PubMed ID: 31555783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
    Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
    Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells.
    Pavlović M; Tadić A; Gligorijević N; Poljarević J; Petrović T; Dojčinović B; Savić A; Radulović S; Grgurić-Šipka S; Aranđelović S
    J Inorg Biochem; 2020 Sep; 210():111155. PubMed ID: 32768729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human topoisomerase inhibition and DNA/BSA binding of Ru(II)-SCAR complexes as potential anticancer candidates for oral application.
    De Grandis RA; de Camargo MS; da Silva MM; Lopes ÉO; Padilha EC; Resende FA; Peccinini RG; Pavan FR; Desideri A; Batista AA; Varanda EA
    Biometals; 2017 Jun; 30(3):321-334. PubMed ID: 28303361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
    Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
    Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
    Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
    Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIα poisoning and DNA double-strand breaking by chiral ruthenium(ii) complexes containing 2-furanyl-imidazo[4,5-f][1,10]phenanthroline derivatives.
    Qian C; Wu J; Ji L; Chao H
    Dalton Trans; 2016 Jun; 45(26):10546-55. PubMed ID: 27226117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human DNA topoisomerase IB by nonmutagenic ruthenium(II)-based compounds with antitumoral activity.
    de Camargo MS; da Silva MM; Correa RS; Vieira SD; Castelli S; D'Anessa I; De Grandis R; Varanda E; Deflon VM; Desideri A; Batista AA
    Metallomics; 2016 Feb; 8(2):179-92. PubMed ID: 26758075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets.
    Guedes APM; Mello-Andrade F; Pires WC; de Sousa MAM; da Silva PFF; de Camargo MS; Gemeiner H; Amauri MA; Gomes Cardoso C; de Melo Reis PR; Silveira-Lacerda EP; Batista AA
    Metallomics; 2020 Apr; 12(4):547-561. PubMed ID: 32108850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
    Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
    Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chiral ruthenium(II) anthraquinone complexes as dual inhibitors of topoisomerases I and II.
    Kou JF; Qian C; Wang JQ; Chen X; Wang LL; Chao H; Ji LN
    J Biol Inorg Chem; 2012 Jan; 17(1):81-96. PubMed ID: 21858685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
    Wang Z; Qian H; Yiu SM; Sun J; Zhu G
    J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruthenium(II) Phosphine/Mercapto Complexes: Their in Vitro Cytotoxicity Evaluation and Actions as Inhibitors of Topoisomerase and Proteasome Acting as Possible Triggers of Cell Death Induction.
    Ribeiro GH; Guedes APM; de Oliveira TD; de Correia CRSTB; Colina-Vegas L; Lima MA; Nóbrega JA; Cominetti MR; Rocha FV; Ferreira AG; Castellano EE; Teixeira FR; Batista AA
    Inorg Chem; 2020 Oct; 59(20):15004-15018. PubMed ID: 32997499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The trans-[Ru(PPh
    Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
    J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruthenium(II) Diphosphine Complexes with Mercapto Ligands That Inhibit Topoisomerase IB and Suppress Tumor Growth In Vivo.
    da Silva MM; Ribeiro GH; de Camargo MS; Ferreira AG; Ribeiro L; Barbosa MIF; Deflon VM; Castelli S; Desideri A; Corrêa RS; Ribeiro AB; Nicolella HD; Ozelin SD; Tavares DC; Batista AA
    Inorg Chem; 2021 Sep; 60(18):14174-14189. PubMed ID: 34477373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metallointercalator [Ru(dppz)
    Yusoh NA; Leong SW; Chia SL; Harun SN; Rahman MBA; Vallis KA; Gill MR; Ahmad H
    ACS Chem Biol; 2020 Feb; 15(2):378-387. PubMed ID: 31898884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.